Showing results (1-10 of 61) with videos related to
Sort By:
Pageof 7
Cell Metabolism|January 10, 2012
Metabolic disease drug discovery- "hitting the target" is easier said than doneDavid E MollerAnnual Review of Medicine|January 31, 2002
The mechanisms of action of PPARsJoel Berger, David E MollerAnnual Review of Medicine|January 22, 2005
Metabolic syndrome: a clinical and molecular perspectiveDavid E Moller, Keith D KaufmanTrends in Endocrinology and Metabolism: TEM|April 9, 2014
FGF21-based pharmacotherapy--potential utility for metabolic disordersRuth E Gimeno, David E MollerEndocrine|April 20, 2006
Modulation of fatty acid metabolism as a potential approach to the treatment of obesity and the metabolic syndromeJun Kusunoki, Akio Kanatani, David E MollerEndocrinology, Diabetes & Metabolism|April 15, 2021
Imeglimin preserves islet β-cell mass in Type 2 diabetic ZDF ratsSophie Hallakou-Bozec, Micheline Kergoat, David E Moller, et al.Plos One|February 19, 2021
Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of actionSophie Hallakou-Bozec, Micheline Kergoat, Pascale Fouqueray, et al.The Journal of Biological Chemistry|November 1, 2002
Salicylic acid reverses phorbol 12-myristate-13-acetate (PMA)- and tumor necrosis factor alpha (TNFalpha)-induced insulin receptor substrate 1 (IRS1) serine 307 phosphorylation and insulin resistance in human embryonic kidney 293 (HEK293) cellsGuoqiang Jiang, Qing Dallas-Yang, Franklin Liu, et al.Cell Biology International|January 24, 2007
Peroxisome proliferator-activated receptor gamma agonists inhibit adipocyte expression of alpha1-acid glycoproteinGino Castriota, G Marie Thompson, Ying Lin, et al.Physiological Reports|March 11, 2022
Reduced lactic acidosis risk with Imeglimin: Comparison with MetforminPierre Theurey, Guillaume Vial, Eric Fontaine, et al.Pageof 7